RxDoctor Payments Data

Amy Littlejohn, PA

Physician Assistant · Springfield, ORNPI 1902884497

Payments from drug & device makers

$1,453in general payments, 2019–2025

Across 34 payments — averaging $42.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$740
  • Intercept Pharmaceuticals, Inc.$225
  • Johnson & Johnson$192
  • Janssen Scientific Affairs, LLC$92
  • Braintree Laboratories, Inc.$63
  • Enterra Medical, Inc.$28
  • plus $114 from 6 others

What the payments were for

  • Food & beverage$1,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,453 in reported general payments places this provider in the 85th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$30,162
Medicare patients
247
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase45$195,856
Humira(Cf) PenAdalimumab26$195,145
XifaxanRifaximin33$112,083
LinzessLinaclotide128$76,987
ZenpepLipase/Protease/Amylase15$56,123
NexiumEsomeprazole Magnesium30$21,274
Mesalamine51$18,026
MotegrityPrucalopride Succinate26$14,920
Mesalamine DrMesalamine14$6,644
MovantikNaloxegol Oxalate16$6,306
Omeprazole322$5,175
Budesonide DrBudesonide25$3,568
Lubiprostone25$2,827
Ursodiol25$2,785
Colestipol Hcl31$2,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$740$272,843173 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$20$112,08333 claims
Aimmune Therapeutics, Inc.Zenpep$23$56,12315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →